Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, CA, USA. ; Vision 21 Cardiac and Vascular Center, Inje University Ilsan Paik Hospital, Goyang, Korea.
Korean Circ J. 2013 Aug;43(8):511-8. doi: 10.4070/kcj.2013.43.8.511.
Animal models have long been developed for cardiovascular research. These animal models have been helpful in understanding disease, discovering potential therapeutics, and predicting efficacy. Despite many efforts, however, translational study has been underestimated. Recently, investigations have identified stem cell treatment as a potentially promising cell therapy for regenerative medicine, largely because of the stem cell's ability to differentiate into many functional cell types. Stem cells promise a new era of cell-based therapy for salvaging the heart. However, stem cells have the potential risk of tumor formation. These properties of stem cells are considered a major concern over the efficacy of cell therapy. The translational/preclinical study of stem cells is essential but only at the beginning stages. What types of heart disease are indicated for stem cell therapy, what type of stem cell, what type of animal model, how do we deliver stem cells, and how do we improve heart function? These may be the key issues that the settlement of which would facilitate the transition of stem cell research from bench to bedside. In this review article, we discuss state-of-the-art technology in stem cell therapies for cardiovascular diseases.
动物模型在心血管研究中一直被广泛应用。这些动物模型在帮助理解疾病、发现潜在治疗方法和预测疗效方面发挥了重要作用。然而，尽管进行了许多努力，转化研究仍然被低估了。最近的研究表明，干细胞治疗可能是一种有前途的再生医学细胞疗法，这主要是因为干细胞具有分化为多种功能细胞类型的能力。干细胞有望为心脏的细胞治疗带来新的时代。然而，干细胞有形成肿瘤的潜在风险。这些干细胞的特性被认为是对细胞治疗疗效的主要关注。干细胞的转化/临床前研究至关重要，但仍处于起步阶段。什么样的心脏病适合干细胞治疗，什么样的干细胞，什么样的动物模型，我们如何输送干细胞，以及如何改善心脏功能？这些可能是解决问题的关键，这些问题的解决将有助于推动干细胞研究从实验室到临床的转化。在这篇综述文章中，我们讨论了用于心血管疾病的干细胞治疗的最新技术。
